Algorithms to improve the EMIAS system to optimize the routing of adolescents with atopic dermatitis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Atopic dermatitis is a systemic, chronic, relapsing, inflammatory disease affecting mainly the skin. In recent decades, the incidence of atopic dermatitis has been steadily increasing. The burden of atopic dermatitis in adolescents is particularly severe because they are in a transitional and vulnerable growth phase with associated biological, cognitive, social, and emotional transformations.

Early and correct diagnosis of atopic dermatitis, as well as the identification of adolescents with an uncontrolled course of the disease, will provide an opportunity to select/change therapy, which can lead to remission, preventing the negative effects of the disease. A number of studies have shown that the negative mental health effects of atopic dermatitis on adolescents include an increased risk for depression, attention deficit hyperactivity disorder, anxiety and behavior disorders, sleep disturbances, and suicidal ideation.

EMIAS is a unified medical information and analytical system, which was created to improve the availability and quality of medical services provided by Moscow public health institutions. The introduction of EMIAS has led to improvements in the healthcare system.

The article proposes validated and simple tools, the integration of which into the EMIAS system, will facilitate the verification of diagnosis and personalized (based on recommendations at the population level) management of adolescents with atopic dermatitis in the outpatient phase by pediatrician and allergist.

About the authors

Anita R. Denisova

The First Sechenov Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: Anita_D@mail.ru
ORCID iD: 0000-0003-0917-6048
SPIN-code: 2924-7732

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

References

  1. Russian Association of Allergologists and Clinical Immunologists (RAAKI). Official website [Internet]. Draft clinical guidelines for atopic dermatitis, 2023. (In Russ). Available from: https://raaci.ru/education/clinic_recomendations.html. Accessed 06.07.2023.
  2. Silverberg J, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi: 10.1016/j.anai.2020.12.020
  3. Kotova E, Kobyakova O, Starodubov V.I., et al. Morbidity of the entire population of Russia in 2020 with a diagnosis established for the first time in life: Statistical materials. Moscow: Central Research Institute of Healthcare Organization and Informatization of the Ministry of Healthcare of the Russian Federation; 2021. 143 р. (In Russ).
  4. Ring J, Zink A, Arents BW, et al. Atopic eczema: Burden of disease and individual suffering: Results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33(7):1331–1340. doi: 10.1111/jdv.15634
  5. Ricci G, Bellini F, Dondi A, et al. Atopic dermatitis in adolescence. Dermatol Reports. 2012;4(1):e1. doi: 10.4081/dr.2012. e1
  6. Laughter M, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: Lessons from the global burden of disease study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi: 10.1111/bjd.19580
  7. Basra M, Finlay A. The family impact of skin diseases: The greater patient concept. Br J Dermatol. 2007;156(5): 929–937. doi: 10.1111/j.1365-2133.2007.07794.x
  8. Lee H, Lee G, Lee J, et al. Psychological stress in parents of children with atopic dermatitis: A cross-sectional study from the Korea national health and nutrition examination survey. Acta Derm Venereol. 2023;(103):adv00844. doi: 10.2340/actadv.v103.2242
  9. Ezzedine K, Shourick J, Merhand S, et al. Impact of atopic dermatitis in adolescents and their parents: A french study. Acta Derm Venereol. 2020;100(17):adv00294. doi: 10.2340/00015555-3653
  10. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. Allergy Clin Immunol. 2013;131(2):428–433. doi: 10.1016/j.jaci.2012.10.041
  11. Horev A, Freud T, Manor I, et al. Risk of attention-deficit/hyperactivity disorder in children with atopic dermatitis. Acta Dermatovenerol Croat. 2017;25(3):210–214.
  12. Kim J, Seo Y. Allergic disease, short sleep duration, and suicidal ideation and plans among Korean adolescents. J Sch Nurs. 2022;38(2):173–183. doi: 10.1177/1059840520921920
  13. Kyung Y, Lee J, Lee JH, et al. Health-related behaviors and mental health states of South Korean adolescents with atopic dermatitis. J Dermatol. 2020;47(7):699–706. doi: 10.1111/1346-8138.15386
  14. Muzzolon M, Muzzolon S, Lima M, et al. Mental disorders and atopic dermatitis in children and adolescents. Adv Dermatol Allergol. 2021;38(6):1099–1104. doi: 10.5114/ada.2021.112280
  15. Da Cruz Sequeira CA. Saúde mental positiva. Conference: Comemorações: Dia Mundial da Saúde Mental. 2015. doi: 10.13140/RG.2.1.3298.3769
  16. Palsson K, Slagor R, Flachs EM, et al. Childhood atopic dermatitis is associated with a decreased chance of completing education later in life: A register-based cohort study. J Eur Acad Dermatol Venereol. 2021;35(9):1849–1858. doi: 10.1111/jdv.17346
  17. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis: Sick leave and job avoidance. J Eur Acad Dermatology Venereol. 2006;20(3):255–259. doi: 10.1111/j.1468-3083.2006.01416.x
  18. Eklund K, Burns M, Oyen K, et al. Addressing chronic absenteeism in schools: A meta-analysis of evidence-based interventions. School Psychol Rev. 2020;51(1):1–17. doi: 10.1080/2372966X.2020.1789436
  19. Cheng B, Silverberg J. Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: A cross-sectional United States population-based study. J Am Acad Dermatol. 2021;85(4):885–892. doi: 10.1016/j.jaad.2021.02.069
  20. Meng Y, Babey S, Wolstein J. Asthma-related school absenteeism and school concentration of low-income students in California. Prev Chronic Dis. 2012;(9):E98. doi: 10.5888/pcd9.110312
  21. Igidyan YA. EMIAS ― as the basis of the software of the Moscow Department of Healthcare. Materials Afanasiev Readings. 2022;(2):29–35. (In Russ).
  22. Wollenberg A, Christen-Zäch S, Taieb A, et al. European task force on atopic dermatitis/EADV eczema task force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892
  23. Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic march: Development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388–398. doi: 10.1111/pde.12867
  24. Bieber T. Atopic dermatitis 2.0: From the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012; 67(12):1475–1482. doi: 10.1111/all.12049
  25. Kleyn C, Barbarot S, Reed C, et al. Burden of moderate to severe atopic dermatitis in adults from france, Italy, and the UK: Patient-Reported outcomes and treatment patterns. Dermatol Ther (Heidelb). 2022;12(8):1947–1965. doi: 10.1007/s13555-022-00777-z
  26. Hill D, Spergel J. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. doi: 10.1016/j.anai.2017.10.037
  27. Charman C, Venn A, Ravenscroft J, Williams H. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–1332. doi: 10.1111/bjd.12590
  28. Pariser D, Simpson E, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: Design, validation and scoring of the atopic dermatitis control tool (ADCT). Curr Med Res Opinion. 2020;36(3):367–376. doi: 10.1080/03007995.2019.1699516
  29. Simpson E, Eckert L, Gadkari A, et al. Validation of the atopic dermatitis control tool (ADCT) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15. doi: 10.1186/s12895-019-0095-3

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Patient referral chart for personalized therapy according to the severity of the disease.

Download (475KB)

Copyright (c) 2023 Pharmarus Print Media

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies